I
0.734
0.01 (0.94%)
| Penutupan Terdahulu | 0.727 |
| Buka | 0.746 |
| Jumlah Dagangan | 385,996 |
| Purata Dagangan (3B) | 3,726,118 |
| Modal Pasaran | 52,810,452 |
| Harga / Buku (P/B) | 2.54 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2025 |
| EPS Cair (TTM) | -1.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.67% |
| Nisbah Semasa (MRQ) | 2.32 |
| Aliran Tunai Operasi (OCF TTM) | -80.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -45.58 M |
| Pulangan Atas Aset (ROA TTM) | -70.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -138.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | IO Biotech, Inc. | Bercampur | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | 0.0 |
| AI Insight | NA |
| Purata | 0.13 |
|
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.36% |
| % Dimiliki oleh Institusi | 66.43% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |